Clinical trials: ESCC
Advanced Esophageal Squamous Cell Carcinoma
To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
This is a phase II study to evaluate the effectiveness and safety of Afininib compared to irinotecan in the 3-gene RNA sequencing (ALTRK) negative advanced esophageal squamous squamous carcinoma.
- Trial name
- NCT05818982
- Testing
- Afatinib, Irinotecan
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Peking University
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant toripalimab combined with chemotherapy and low-dose radiotherapy in patients with esophageal squamous cell carcinoma who are insensitive to…
- Trial name
- NCT07272291
- Testing
- Toripalimab
- Volunteers
- 48 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a prospective, single-arm, open-label，multi-center, phase Ib/II study, aiming to evaluate the efficacy and safety of Fruquintinib combined With Cadonilimab (AK104) and Tegafur，Gimeracil and Oteracil Potassium in patients…
- Trial name
- NCT06487702
- Testing
- fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Rui-hua Xu, MD, PhD
Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by conversion surgery, in patients with locally advanced…
- Trial name
- NCT07039162
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Ming-Yu Lien
Esophageal Cancer
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma. Aim to find the difference in efficacy and safety between tirilizumab combined with concurrent chemoradiation…
- Trial name
- TCRTOE (NCT06061146)
- Testing
- Arm A, Arm B
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced/Metastatic/Recurrent ESCC
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line…
- Trial name
- NCT07417735
- Testing
- SYS6010, Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel)
- Volunteers
- 436 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
ESCC, Tislelizumab
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor worldwide, with particularly high incidence in East Asian regions such as China, and is associated with poor patient prognosis.
- Conditions
- ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin
- Trial name
- NCT07531979
- Testing
- Tislelizumab, Becotatug Vedotin, Cisplatin
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Esophageal Squamous Cell Carcinoma (ESCC)
Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
The combination of programmed death receptor 1 (PD-1) inhibitors with chemotherapy has been recognized for the treatment of advanced and metastatic esophageal squamous cell carcinoma (ESCC).
- Trial name
- ESO-Nanjing12 (NCT07016737)
- Testing
- Sintilimab Combined With Docetaxel Monotherapy
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Ye jinjun
Esophageal Cancer
Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)
This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (DCF) in unresectable…
- Trial name
- NCT00915850
- Testing
- DCF
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Wakayama Medical University
Esophagus Cancer
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
Prediction for pCR After Neoadjuvant Immunotherapy Combined With Chemotherapy Using Single-Cell RNA Sequencing in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Trial name
- NCT05807542
- Testing
- Tislelizumab, Paclitaxel-albumin, Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Cancer
Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used.
- Trial name
- NCT07549269
- Testing
- The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.
- Where
- 3 sites in China
- Volunteers
- 387 people
- Sponsor
- Sichuan University
Esophageal Cancer
ESI With EUS to Differentiate T3 and T4 ESCC
By using a novel technique of extraesophageal saline injection (ESI),the esophagus is to be separate from the adjacent organs.The space between esophagus and adjacent organs can be detected by endoscopic ultrasonography enhanced…
- Trial name
- ESI (NCT01930630)
- Testing
- Extraesophageal saline injection (ESI)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Metastatic Esophageal Squamous Cell Carcinoma
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
- Trial name
- NCT05142709
- Testing
- Anti-PD-1 Immune Checkpoint Inhibitors
- Where
- 23 sites in China
- Volunteers
- 1,197 people
- Sponsor
- Fudan University
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Non-small Cell Lung Cancer, Head and Neck Cancer
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03518554
- Testing
- JAB-3068
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Esophageal Squamous Cell Carcinoma
Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
To evaluate the effectiveness and safety of anlotinib combined with TQB2450 (PD-L1 inhibitor) in the first-line treatment of patients with advanced ESCC.
- Trial name
- NCT05038813
- Testing
- Anlotinib+TQB2450
- Where
- 5 sites in China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Carcinoma
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
This is a single-arm, exploratory clinical study.
- Trial name
- NCT07490002
- Testing
- Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel
- Volunteers
- 33 people
- Sponsor
- Changhai Hospital
Esophageal Squamous Cell Carcinoma
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
This is a prospective, single-arm, open-label，multi-center, phase II study, aiming to evaluate the efficacy and safety of AK104 combined with preoperative chemotherapy in patients with locally advanced ESCC.
- Trial name
- NCT05896787
- Testing
- AK104, nab-paclitaxel, carboplatin
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma (ESCC)
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)
This is an open-label, single arm, multi-center study, assessing efficacy and safety of BI-754091 in combination with afatinib as treatment in patients with advanced or metastatic ESCC refractory to at least 1 line of systemic…
- Trial name
- BEAR (NCT04839471)
- Testing
- BI-754091 plus afatinib
- Where
- 4 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- National Health Research Institutes, Taiwan